HeartFlow Inc. (HTFL) shares reached an all-time high of $48.70 on Wednesday, extending a sharp rally driven by robust revenue growth and beating earnings expectations.
The diagnostics company’s stock is now trading just 1% below its 52-week peak, reflecting a six-month gain of 86% and a 65.54% increase over the past year. Revenue in the second quarter of 2026 climbed 43% year-over-year, with the company reporting $64.1 million in sales. This exceeded both Stifel’s projection of $56.7 million and the consensus estimate of $56.6 million.
HeartFlow’s adjusted earnings per share came in at negative $0.07, beating Wall Street’s forecast of negative $0.19. The company attributed the performance to rising demand for coronary artery disease diagnostics, particularly in its plaque and FFRCT businesses.
Analysts at Stifel upgraded their outlook, lifting the price target for HeartFlow shares from $40 to $45 while maintaining a Buy rating. The firm’s upgrade follows the revenue and earnings beat, which underscored the company’s accelerating growth trajectory.
HeartFlow’s stock surge comes amid broader investor optimism toward medical technology firms focused on cardiovascular diagnostics. The company’s recent performance has outpaced several Wall Street projections, positioning it as a standout in the sector.
